Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Novel oestrogen receptor β-selective ligand reduces obesity and depressive-like behaviour in ovariectomized mice.

Tytuł :
Novel oestrogen receptor β-selective ligand reduces obesity and depressive-like behaviour in ovariectomized mice.
Autorzy :
Sasayama D; Department of Psychiatry, Shinshu University School of Medicine, Matsumoto, Nagano, 390-8621, Japan.
Sugiyama N; Department of Psychiatry, Shinshu University School of Medicine, Matsumoto, Nagano, 390-8621, Japan. .; Department of Applied Occupational Therapy, Shinshu University School of Health Sciences, Matsumoto, Nagano, 390-8621, Japan. .
Yonekubo S; Discovery Research I, R&D, Kissei Pharmaceutical Co., Ltd., 4365-1 Kashiwabara, Hotaka, Azumino, Nagano, 399-8304, Japan.
Pawlak A; Nihon Bioresearch Inc. 6-104, Majima, Fukuju-cho, Hashima, Gifu, 501-6251, Japan.
Murasawa H; Nihon Bioresearch Inc. 6-104, Majima, Fukuju-cho, Hashima, Gifu, 501-6251, Japan.
Nakamura M; Nihon Bioresearch Inc. 6-104, Majima, Fukuju-cho, Hashima, Gifu, 501-6251, Japan.
Hayashi M; Safety Research Laboratory, R&D, Kissei Pharmaceutical Co., Ltd., 2320-1 Maki, Azumino, Nagano, 399-8304, Japan.
Ogawa T; Safety Research Laboratory, R&D, Kissei Pharmaceutical Co., Ltd., 2320-1 Maki, Azumino, Nagano, 399-8304, Japan.
Moro M; Biologics Research, R&D, Kissei Pharmaceutical Co., Ltd., 4365-1 Kashiwabara, Hotaka, Azumino, Nagano, 399-8304, Japan.
Washizuka S; Department of Psychiatry, Shinshu University School of Medicine, Matsumoto, Nagano, 390-8621, Japan.
Amano N; Department of Drug Discovery Science, Shinshu University School of Medicine, Matsumoto, Nagano, 390-8621, Japan.
Hongo K; Department of Drug Discovery Science, Shinshu University School of Medicine, Matsumoto, Nagano, 390-8621, Japan.
Ohnota H; Department of Drug Discovery Science, Shinshu University School of Medicine, Matsumoto, Nagano, 390-8621, Japan.
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2017 Jul 05; Vol. 7 (1), pp. 4663. Date of Electronic Publication: 2017 Jul 05.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Język :
English
Imprint Name(s) :
Original Publication: London : Nature Publishing Group, copyright 2011-
MeSH Terms :
Depression/*drug therapy
Estradiol/*administration & dosage
Estrogen Receptor beta/*metabolism
Obesity/*drug therapy
Selective Estrogen Receptor Modulators/*administration & dosage
Animals ; Depression/chemically induced ; Depression/metabolism ; Disease Models, Animal ; Estradiol/adverse effects ; Female ; Ligands ; Mice ; Molecular Structure ; Obesity/chemically induced ; Obesity/metabolism ; Organ Size/drug effects ; Ovariectomy ; Postmenopause ; Selective Estrogen Receptor Modulators/chemistry ; Selective Estrogen Receptor Modulators/pharmacology ; Uterus/drug effects ; Weight Gain/drug effects
References :
FEBS J. 2015 Mar;282(6):1126-36. (PMID: 25612677)
Maturitas. 2002 May 20;42(1):71-5. (PMID: 12020982)
Bioorg Med Chem. 2016 Nov 15;24(22):5895-5910. (PMID: 27692995)
Pharmacol Biochem Behav. 2012 Mar;101(1):85-7. (PMID: 22197713)
Psychoneuroendocrinology. 2017 Mar;77:25-36. (PMID: 28012291)
Cancer Lett. 2006 Jan 18;231(2):151-7. (PMID: 16399219)
Endocrinology. 2009 Apr;150(4):1817-25. (PMID: 19074580)
Biol Psychiatry. 2008 Sep 15;64(6):521-6. (PMID: 18597740)
Behav Pharmacol. 2010 May;21(3):231-40. (PMID: 20480545)
N Engl J Med. 1975 Dec 4;293(23):1167-70. (PMID: 171569)
Endocrinology. 2003 Oct;144(10):4241-9. (PMID: 14500559)
J Clin Psychopharmacol. 2008 Dec;28(6):721-2. (PMID: 19011455)
Mol Cancer Ther. 2007 Oct;6(10):2626-33. (PMID: 17913855)
Mol Hum Reprod. 2014 Aug;20(8):776-86. (PMID: 24770950)
Biol Pharm Bull. 2009 Sep;32(9):1576-83. (PMID: 19721235)
Neurobiol Aging. 2016 Jan;37:179-91. (PMID: 26686671)
Cochrane Database Syst Rev. 2012 Aug 15;(8):CD000402. (PMID: 22895916)
Mol Psychiatry. 2013 Jun;18(6):674-80. (PMID: 22665260)
Behav Brain Res. 2013 Jan 1;236(1):180-5. (PMID: 22981560)
Sci Rep. 2016 May 11;6:25878. (PMID: 27165125)
Psychopharmacology (Berl). 2005 Nov;182(3):335-44. (PMID: 16001105)
Diabetes Obes Metab. 2006 Sep;8(5):538-54. (PMID: 16918589)
Depress Anxiety. 2015 Aug;32(8):539-49. (PMID: 26130315)
Bone Miner. 1994 Jan;24(1):43-58. (PMID: 8186733)
Mol Psychiatry. 2009 Feb;14 (2):223-32, 117. (PMID: 18982005)
Horm Behav. 2013 Feb;63(2):361-9. (PMID: 23262264)
J Clin Psychiatry. 2007 Apr;68(4):636-7. (PMID: 17474826)
Arch Gen Psychiatry. 2006 Apr;63(4):385-90. (PMID: 16585467)
PLoS One. 2012;7(9):e44787. (PMID: 22970307)
J Biol Chem. 2010 Oct 8;285(41):31292-303. (PMID: 20657011)
J Vis Exp. 2012 Jan 29;(59):e3638. (PMID: 22314943)
Int J Obes Relat Metab Disord. 2002 Aug;26(8):1103-9. (PMID: 12119576)
Trends Endocrinol Metab. 2010 Sep;21(9):545-52. (PMID: 20646931)
JAMA. 2012 Feb 1;307(5):491-7. (PMID: 22253363)
Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2859-63. (PMID: 19196965)
Neuroreport. 2014 Jan 22;25(2):100-4. (PMID: 24128867)
J Steroid Biochem Mol Biol. 2015 Nov;154:12-22. (PMID: 26134426)
Psychopharmacology (Berl). 2005 Dec;183(3):300-7. (PMID: 16228195)
Physiol Behav. 1989 May;45(5):1067-8. (PMID: 2780868)
Substance Nomenclature :
0 (Estrogen Receptor beta)
0 (Ligands)
0 (Selective Estrogen Receptor Modulators)
4TI98Z838E (Estradiol)
Entry Date(s) :
Date Created: 20170707 Date Completed: 20190128 Latest Revision: 20190128
Update Code :
20210623
PubMed Central ID :
PMC5498485
DOI :
10.1038/s41598-017-04946-5
PMID :
28680060
Czasopismo naukowe
Hormonal changes due to menopause can cause various health problems including weight gain and depressive symptoms. Multiple lines of evidence indicate that oestrogen receptors (ERs) play a major role in postmenopausal obesity and depression. However, little is known regarding the ER subtype-specific effects on obesity and depressive symptoms. To delineate potential effects of ERβ activation in postmenopausal women, we investigated the effects of a novel oestrogen receptor β-selective ligand (C-1) in ovariectomized mice. Uterine weight, depressive behaviour, and weight gain were examined in sham-operated control mice and ovariectomized mice administered placebo, C-1, or 17β-oestradiol (E2). Administration of C-1 or E2 reduced body weight gain and depressive-like behaviour in ovariectomized mice, as assessed by the forced swim test. In addition, administration of E2 to ovariectomized mice increased uterine weight, but administration of C-1 did not result in a significant increase in uterine weight. These results suggest that the selective activation of ERβ in ovariectomized mice may have protective effects against obesity and depressive-like behaviour without causing an increase in uterine weight. The present findings raise the possibility of the application of ERβ-ligands such as C-1 as a novel treatment for obesity and depression in postmenopausal women.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies